Results 171 to 180 of about 80,577 (303)

A meta-analysis of the efficacy and safety of Janus kinase inhibitors in patients with ulcerative colitis. [PDF]

Medicine (Baltimore)
Yang Q, Yan Y.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Therapeutic Outcomes of Janus Kinase Inhibitors in Refractory Nail Lichen Planus: A Systematic Review. [PDF]

Cureus
Aqeel S, Hannani H, Mojiri ME, Otaif FA, Alsaadi GM, Alghamdi AA, Alammari FF, Alkhudairy SK, Alzahrani HA, Akkam MM.   +9 more
europepmc   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Resolution of Hashimoto thyroiditis with Janus kinase inhibitor therapy in a patient with alopecia universalis. [PDF]

JCEM Case Rep
Trost SU, Radulescu A.
europepmc   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Efficacy of abrocitinib in patients with atopic dermatitis resistant to Janus kinase inhibitors. [PDF]

Skin Health Dis
Ippoliti E, Gori N, Coscarella G, Antonelli F, Cannizzaro MV, Peris K.   +5 more
europepmc   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Public Interest in Janus Kinase (JAK) Inhibitors for Alopecia Areata: A Google Trend Analysis. [PDF]

JMIR Dermatol
Howard J, Kamili NAH, Idris H, Krueger LD.   +3 more
europepmc   +1 more source